Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | HPGD | P15428 | 7/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191988 | 0.91 | HPGD (0.71) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL7565913 | 0.91 | RAB9A (0.81) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL13665249 | 0.90 | RAB9A (0.78) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL7565917 | 0.88 | RAB9A (0.72) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL10192012 | 0.87 | HPGD (0.56) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL12285188 | 0.87 | RAB9A (0.74) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL3424143 | 0.86 | MAPK1 (0.69) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL27422626 | 0.85 | RAB9A (0.72) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL27308926 | 0.84 | RAB9A (0.61) | RAB9AHPGDLMNANPC1SMN1; SMN2 | |
| SCHEMBL11218133 | 0.84 | EPHX2 (0.79) | RAB9AHPGDLMNANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | RAB9A 3975/4885HPGD 1033/4885LMNA 3101/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | RAB9A 2829/4885HPGD 3255/4885LMNA 1012/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | RAB9A 2829/4885HPGD 3255/4885LMNA 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.